To validate the findings, we carried out orthogonal validation using an external cohort of 110 patients with NSCLC (55 LUAD and 55 LUSC) and immunohistochemistry staining for neutrophils, CD4+ T cells, and macrophages. The gene discussed is CD4; the disease is non-small cell lung carcinoma.